Edwards Lifesciences (EW) Receivables - Other (2009 - 2026)

Edwards Lifesciences has reported Receivables - Other for 18 years, with the latest figure at $197.3 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 138.57% year-over-year to $197.3 million; the trailing twelve-month figure through Mar 2026 stood at $197.3 million (up 138.57% YoY), and the FY2025 full-year result was $252.5 million, up 113.44% from the prior year.
• Receivables - Other for Q1 2026 stood at $197.3 million, down from $252.5 million in the prior quarter.
• The five-year high for Receivables - Other was $252.5 million in Q4 2025, with the low at $42.8 million in Q2 2022.
• Average Receivables - Other over 5 years is $100.1 million, with a median of $62.3 million recorded in 2023.
• Year-over-year, Receivables - Other plunged 35.78% in 2022 and jumped 266.49% in 2025.
• Tracing EW's Receivables - Other over 5 years: stood at $56.1 million in 2022, then grew by 0.89% to $56.6 million in 2023, then surged by 109.01% to $118.3 million in 2024, then jumped by 113.44% to $252.5 million in 2025, then decreased by 21.86% to $197.3 million in 2026.
• The last three Receivables - Other figures came in at $197.3 million (Q1 2026), $252.5 million (Q4 2025), and $199.5 million (Q3 2025), per Business Quant data.

Peer Comparison